Guttify, a premium gut health startup by Lifechart, has announced that the company is currently in advanced discussions with leading venture capital firms to raise INR 20 crore in its upcoming funding round.
The company is known for its “Diagnosis-First” approach to solving gut health issues from the core and has already gained early momentum in the wellness and consumer healthcare segments. Sources reveal that 60% of the round is expected to be closed with a well-known VC firm specialising in healthcare and consumer investments.
Adding to its credibility, Guttify recently onboarded Prashant Pitti (Founder, EaseMyTrip & Optimio) as a strategic advisor and investor. Backed by UNICHEM Laboratories’ family office and existing investors. The brand has recently raised $360,000 in extended seed funding in May 2025, taking its current total funding to over $1 million. The funds will be used for the expansion of its diagnosis-first, at-home gut wellness solutions across urban and semi-urban India.
“Our mission has always been to help people solve chronic gut health issues from the core using the power of science and diagnostics. The new funding will be used to scale product development, expand distribution, and invest in research to further enhance personalized gut care solutions,” said Mukul Shah, co-founder at Guttify.
As part of its next innovation cycle, Guttify is gearing up to launch India’s first-of-its-kind RNA gene-based DIY gut testing kits, designed to offer results within 24 hours. This affordable, at-home solution aims to democratise gut health testing and empower individuals to better understand and manage their digestive health without the need for invasive procedures or clinic visits.
Got a story that Healthcare Executive should dig into? Shoot it over to arunima.rajan@hosmac.com—no PR fluff, just solid leads.
